Roche Holding AG, a global leader in pharmaceuticals and diagnostics, announced that it is expanding its monitoring portfolio through its merger with Sullivan client SAGA Diagnostics AB. The transaction is valued at up to $595 million, inclusive of commercial and regulatory milestone payments.

SAGA Diagnostics developed a next-generation, tumor-informed molecular residual disease (MRD) platform. Sullivan supported the company in developing and implementing its patent strategy. The team advising SAGA Diagnostics included partner Thomas Meyers and associates Sung Min Yoon and Eleesya Cordes.

Read the full press release here.